Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tissue factor pathway inhibitor (TFPI)--an update

P M Sandset1

  • 1Haematology Research Laboratory, Ullevaal University Hospital, Oslo, Norway. perms@ulrik.uio.no

Haemostasis
|October 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification and evaluation of Pharmacological enhancers of the factor VII p.Q160R variant.

Scientific reports·2025
Same author

Genome-wide analysis of genetic determinants of circulating factor VII-activating protease (FSAP) activity.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome.

Thrombosis research·2018
Same author

Healthcare utilisation, induced labour and caesarean section in the pregnancy after stillbirth: a prospective study.

BJOG : an international journal of obstetrics and gynaecology·2017
Same author

Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Antiphospholipid Antibodies are Associated with Low Levels of Complement C3 and C4 in Patients with Systemic Lupus Erythematosus.

Scandinavian journal of immunology·2016
Same journal

Thrombosis and Haemostasis Issues in Cancer. International Conference. Bergamo, Italy, 2-4 November 2001. Lectures and abstracts.

Haemostasis·2002
Same journal

Biochemistry of cancer procoagulant.

Haemostasis·2002
Same journal

Management of thromboembolic disease in cancer patients.

Haemostasis·2002
Same journal

An overview of thromboprophylaxis in malignancy.

Haemostasis·2002
Same journal

Platelets cross-talk with tumor cells.

Haemostasis·2002
Same journal

Properties and function of heparanase in cancer metastasis and angiogenesis.

Haemostasis·2002
See all related articles

Tissue factor pathway inhibitor (TFPI) is a natural anticoagulant. Research explores TFPI's role in thrombosis, its interaction with heparin, and its function in atherosclerosis.

Area of Science:

  • Coagulation and Thrombosis Research
  • Vascular Biology
  • Biochemistry

Background:

  • Tissue factor pathway inhibitor (TFPI) is a key natural anticoagulant.
  • Experimental models show TFPI's protective role against thrombosis and disseminated intravascular coagulation.
  • The precise role of TFPI in coagulation and its associated mutations remain under investigation.

Purpose of the Study:

  • To summarize current research on TFPI, focusing on its cell biology, interaction with heparin, and lipoprotein-associated TFPI.
  • To investigate the mechanisms of TFPI release and degradation.
  • To elucidate the cooperative anticoagulant mechanisms involving TFPI and other factors.

Main Methods:

  • Review of experimental evidence and current research on TFPI.

Related Experiment Videos

  • Analysis of TFPI's role in various coagulation models.
  • Investigation of TFPI's interaction with heparin, endothelial cells, and lipoprotein-associated forms.

    • Main Results:

    • TFPI is constitutively produced by endothelial cells and bound to their surface, readily released by heparin.
    • Low-density lipoprotein receptor-related protein mediates TFPI degradation in some cell lines.
    • TFPI significantly contributes to the postheparin anticoagulant effect and cooperates with antithrombin to inhibit coagulation activation.

    Conclusions:

    • TFPI plays a critical role as a natural anticoagulant, influencing thrombosis and disseminated intravascular coagulation.
    • Further research is needed to identify TFPI mutations linked to thrombosis and to fully understand lipoprotein-associated TFPI's role, particularly in atherosclerosis.